{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:15:29Z","timestamp":1761743729359},"reference-count":30,"publisher":"Scientific Scholar","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Palliat Care"],"published-print":{"date-parts":[[2013]]},"DOI":"10.4103\/0973-1075.110239","type":"journal-article","created":{"date-parts":[[2013,4,8]],"date-time":"2013-04-08T06:51:11Z","timestamp":1365403871000},"page":"58","source":"Crossref","is-referenced-by-count":1,"title":["A Modified method for reducing renal injury in zoledronic acid treatment of hypercalcemia and adverse skeletal events"],"prefix":"10.25259","volume":"19","author":[{"given":"Yan","family":"Pang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keli","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"key":"key-10.4103\/0973-1075.110239-1","doi-asserted-by":"crossref","unstructured":"Price PA, Caputo JM, Williamson MK. Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: Biochemical evidence for the cancellous bone-remodeling compartment. J Bone Miner Res 2002;17:1171-9.","DOI":"10.1359\/jbmr.2002.17.7.1171"},{"key":"key-10.4103\/0973-1075.110239-2","first-page":"S3","volume-title":"The molecular basis of bisphosphonate activity: A preclinical perspective","author":"Green","year":"2010","journal-title":"Semin Oncol"},{"key":"key-10.4103\/0973-1075.110239-3","first-page":"S50","volume-title":"Clemons M.A primer of bone metastases management in breast cancer patients","author":"Petrut","year":"2008","journal-title":"Curr Oncol"},{"key":"key-10.4103\/0973-1075.110239-4","first-page":"382","volume-title":"A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer","author":"Zaghloul","year":"2010","journal-title":"Int J Clin Oncol"},{"key":"key-10.4103\/0973-1075.110239-5","first-page":"18","volume-title":"Direct effects of bisphosphonates on breast cancer cells","author":"Senaratne","year":"2002","journal-title":"Breast Cancer Res"},{"key":"key-10.4103\/0973-1075.110239-6","first-page":"R4","volume-title":"Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells","author":"Journ\u00e9","year":"2008","journal-title":"Breast Cancer Res"},{"key":"key-10.4103\/0973-1075.110239-7","first-page":"1809","volume-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0973-1075.110239-8","first-page":"261","volume-title":"Zoledronic acid in the management of metastatic bone disease","author":"Polascik","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"key-10.4103\/0973-1075.110239-9","first-page":"5","volume-title":"Zoledronic acid in metastatic bone disease: an audit based discussion","author":"Akbar","year":"2010","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"key-10.4103\/0973-1075.110239-10","first-page":"1137","volume-title":"Zoledronic acid in the treatment of bonemetastases by hepatocellular carcinoma: A case series","author":"Montella","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"key-10.4103\/0973-1075.110239-11","first-page":"32","volume-title":"Results of a multicenter open-label randomized trial evaluating infusion duration of zoledronic acid in multiple myeloma patients (the ZMAX trial)","author":"Berenson","year":"2011","journal-title":"J Support Oncol"},{"key":"key-10.4103\/0973-1075.110239-12","first-page":"13","volume-title":"Significant pain relief with loading dose zoledronic acid in bone metastases is only seen in patients with elevated initial serum C telopeptide (CTX)","author":"Dekoninck","year":"2011","journal-title":"Pragmat Observ Res"},{"key":"key-10.4103\/0973-1075.110239-13","first-page":"281","volume-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","author":"Markowitz","year":"2003","journal-title":"Kidney Int"},{"key":"key-10.4103\/0973-1075.110239-14","first-page":"687","volume-title":"Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy","author":"Vogel","year":"2004","journal-title":"Oncologist"},{"key":"key-10.4103\/0973-1075.110239-15","first-page":"1211","volume-title":"Clinical efficacy and safety of zoledronic acid in prostate and breast cancer","author":"Doggrell","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"key-10.4103\/0973-1075.110239-16","first-page":"306","volume-title":"The issue of renal safety of zoledronic acid from a nephrologist\u2032s point of view","author":"Balla","year":"2005","journal-title":"Oncologist"},{"key":"key-10.4103\/0973-1075.110239-17","first-page":"319","volume-title":"Safety and convenience of a 15-minute infusion of zoledronic acid","author":"Berenson","year":"2004","journal-title":"Oncologist"},{"key":"key-10.4103\/0973-1075.110239-18","first-page":"S4","volume-title":"The dental implications of bisphosphonates and bone disease","author":"Cheng","year":"2005","journal-title":"Aust Dent J"},{"key":"key-10.4103\/0973-1075.110239-19","first-page":"897","volume-title":"Management of the adverse effects associated with intravenous bisphosphonates","author":"Tanvetyanon","year":"2006","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0973-1075.110239-20","first-page":"911","volume-title":"High renal activity on bone scintigrams.A sign of Hypercalcemia?","author":"Buxton-Thomas","year":"1983","journal-title":"Br J Radiol"},{"key":"key-10.4103\/0973-1075.110239-21","first-page":"149","volume-title":"Nonosseous abnormalities on bone scans","author":"Loutfi","year":"2003","journal-title":"J Nucl Med Technol"},{"key":"key-10.4103\/0973-1075.110239-22","first-page":"153","volume-title":"Acute renal failure and hypercalcemia","author":"Moys\u00e9s-Neto","year":"2006","journal-title":"Ren Fail"},{"key":"key-10.4103\/0973-1075.110239-23","first-page":"80","volume-title":"Bisphosphonates: Mechanisms of action","author":"Fleisch","year":"1998","journal-title":"Endocr Rev"},{"key":"key-10.4103\/0973-1075.110239-24","first-page":"241","volume-title":"Bisphosphonate treatment of lytic bone metastases","author":"Lipton","year":"1999","journal-title":"Drugs Aging"},{"key":"key-10.4103\/0973-1075.110239-25","first-page":"233","volume-title":"Multiple myeloma, severe Hypercalcemia, acute renal failure and multiple organ failure due to calcinosis","author":"Heras","year":"2011","journal-title":"Nefrologia"},{"key":"key-10.4103\/0973-1075.110239-26","first-page":"333","volume-title":"Usefulness of 99m Tc-Methylene Diphosphonate Scintigraphy in Nephrocalcinosis","author":"Bossuyt","year":"1979","journal-title":"Clin Nucl Med"},{"key":"key-10.4103\/0973-1075.110239-27","first-page":"1243","volume-title":"Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases","author":"Chapuy","year":"1980","journal-title":"J Clin Invest"},{"key":"key-10.4103\/0973-1075.110239-28","first-page":"481","volume-title":"The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy","author":"Major","year":"2002","journal-title":"Oncologist"},{"key":"key-10.4103\/0973-1075.110239-29","first-page":"893","volume-title":"Bisphosphonates for bone pain","author":"Weinstein","year":"2010","journal-title":"J Palliat Med"},{"key":"key-10.4103\/0973-1075.110239-30","first-page":"903","volume-title":"Hypercalcemia and metastatic bone disease: Is there a causal link?","author":"Ralston","year":"1982","journal-title":"Lancet"}],"container-title":["Indian Journal of Palliative Care"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T15:07:09Z","timestamp":1626275229000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jpalliativecare.com\/text.asp?2013\/19\/1\/58\/110239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"alternative-id":["110239"],"URL":"https:\/\/doi.org\/10.4103\/0973-1075.110239","relation":{},"ISSN":["0973-1075"],"issn-type":[{"value":"0973-1075","type":"print"}],"subject":[],"published":{"date-parts":[[2013]]}}}